ST宜化(000422.SZ):新疆天運合成氨尿素裝置臨時停產
格隆匯12月17日丨ST宜化(000422.SZ)公佈,公司於2020年12月17日接到公司子公司新疆天運化工有限公司(以下簡稱“新疆天運”)的通知,因冬季天然氣供應受限,新疆天運年產30萬噸合成氨52萬噸尿素裝置於2020年12月17日起全部停產。
新疆天運本次臨時停產預計減少公司2020年度營業收入3339萬元,減少歸屬於母公司所有者的淨利潤約145萬元左右;該預計是公司財務部門初步測算的結果,具體數據應以公司2020年年度審計數據為準。公司將積極協調新疆天運的天然氣供應,爭取使新疆天運早日恢復生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.